The latest price target for Zymeworks (NASDAQ:ZYME) was reported by Leerink Partners on November 7, 2024. The analyst firm set a price target for $25.00 expecting ZYME to rise to within 12 months (a possible 83.15% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Zymeworks (NASDAQ:ZYME) was provided by Leerink Partners, and Zymeworks upgraded their outperform rating.

The last upgrade for Zymeworks Inc happened on November 7, 2024 when Leerink Partners raised their price target to $25. Leerink Partners previously had a market perform for Zymeworks Inc.

The last downgrade for Zymeworks Inc happened on November 1, 2024 when Wells Fargo changed their price target from $12 to $12 for Zymeworks Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zymeworks, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zymeworks was filed on November 7, 2024 so you should expect the next rating to be made available sometime around November 7, 2025.

While ratings are subjective and will change, the latest Zymeworks (ZYME) rating was a upgraded with a price target of $10.00 to $25.00. The current price Zymeworks (ZYME) is trading at is $13.65, which is within the analyst’s predicted range.